Literature DB >> 17637610

ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia.

Dilip V Jeste1, Dan Blazer, Daniel Casey, Thomas Meeks, Carl Salzman, Lon Schneider, Pierre Tariot, Kristine Yaffe.   

Abstract

In elderly persons, antipsychotic drugs are clinically prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications (schizophrenia and bipolar disorder). The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia. In April 2005, the FDA, based on a meta-analysis of 17 double-blind randomized placebo-controlled trials among elderly people with dementia, determined that atypical antipsychotics were associated with a significantly (1.6-1.7 times) greater mortality risk compared with placebo, and asked that drug manufacturers add a 'black box' warning to prescribing information for these drugs. Most deaths were due to either cardiac or infectious causes, the two most common immediate causes of death in dementia in general. Clinicians, patients, and caregivers are left with unclear choices of treatment for dementia patients with psychosis and/or severe agitation. Not only are psychosis and agitation common in persons with dementia but they also frequently cause considerable caregiver distress and hasten institutionalization of patients. At the same time, there is a paucity of evidence-based treatment alternatives to antipsychotics for this population. Thus, there is insufficient evidence to suggest that psychotropics other than antipsychotics represent an overall effective and safe, let alone better, treatment choice for psychosis or agitation in dementia; currently no such treatment has been approved by the FDA for these symptoms. Similarly, the data on the efficacy of specific psychosocial treatments in patients with dementia are limited and inconclusive. The goal of this White Paper is to review relevant issues and make clinical and research recommendations regarding the treatment of elderly dementia patients with psychosis and/or agitation. The role of shared decision making and caution in using pharmacotherapy for these patients is stressed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17637610      PMCID: PMC2553721          DOI: 10.1038/sj.npp.1301492

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  107 in total

Review 1.  Differences between caregivers and noncaregivers in psychological health and physical health: a meta-analysis.

Authors:  Martin Pinquart; Silvia Sörensen
Journal:  Psychol Aging       Date:  2003-06

2.  Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.

Authors:  Lon S Schneider; M Saleem Ismail; Karen Dagerman; Sonia Davis; Jason Olin; Dennis McManus; Eric Pfeiffer; J Michael Ryan; David L Sultzer; Pierre N Tariot
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

3.  Clinical trials in late-life depression: revisited.

Authors:  Steven P Roose; Harold A Sackeim
Journal:  Am J Geriatr Psychiatry       Date:  2002 Sep-Oct       Impact factor: 4.105

Review 4.  Aggression in the elderly.

Authors:  Henry Brodaty; Lee-Fay Low
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

Review 5.  Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.

Authors:  Nhi-Ha Trinh; Jennifer Hoblyn; Subhanjoy Mohanty; Kristine Yaffe
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

6.  A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.

Authors:  Sanford I Finkel; Jacobo E Mintzer; Maurice Dysken; K R R Krishnan; Tal Burt; Thomas McRae
Journal:  Int J Geriatr Psychiatry       Date:  2004-01       Impact factor: 3.485

7.  Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients.

Authors:  Christian R Dolder; Dilip V Jeste
Journal:  Biol Psychiatry       Date:  2003-06-15       Impact factor: 13.382

8.  Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial.

Authors:  Rob C Sival; P M Judith Haffmans; Paul A F Jansen; Sijmen A Duursma; Piet Eikelenboom
Journal:  Int J Geriatr Psychiatry       Date:  2002-06       Impact factor: 3.485

9.  A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

Authors:  Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

10.  Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease.

Authors:  Rochelle E Tractenberg; Myron F Weiner; Marian B Patterson; Linda Teri; Leon J Thal
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-06       Impact factor: 2.680

View more
  92 in total

1.  Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients.

Authors:  Krista F Huybrechts; M Alan Brookhart; Kenneth J Rothman; Rebecca A Silliman; Tobias Gerhard; Stephen Crystal; Sebastian Schneeweiss
Journal:  Am J Epidemiol       Date:  2011-09-20       Impact factor: 4.897

2.  Pharmacotherapy for late-life depression.

Authors:  George S Alexopoulos
Journal:  J Clin Psychiatry       Date:  2011-01       Impact factor: 4.384

3.  Psychotropic medication burden and factors associated with antipsychotic use: an analysis of a population-based sample of community-dwelling older persons with dementia.

Authors:  YongJoo Rhee; John G Csernansky; Linda L Emanuel; Chang-Gok Chang; Joseph W Shega
Journal:  J Am Geriatr Soc       Date:  2011-09-23       Impact factor: 5.562

Review 4.  Challenge of changing nursing home prescribing culture.

Authors:  Jennifer Tjia; Jerry H Gurwitz; Becky A Briesacher
Journal:  Am J Geriatr Pharmacother       Date:  2012-01-20

5.  An analysis of the intended use of atypical antipsychotics in dementia.

Authors:  Jeff Ventimiglia; Amir H Kalali; Ipsit V Vahia; Dilip V Jeste
Journal:  Psychiatry (Edgmont)       Date:  2010-11

6.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

7.  Antipsychotic Use in a Diverse Population With Dementia: A Retrospective Review of the National Alzheimer's Coordinating Center Database.

Authors:  Glen L Xiong; Teresa Filshtein; Laurel A Beckett; Ladson Hinton
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2015       Impact factor: 2.198

8.  Association of the Centers for Medicare & Medicaid Services' National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014.

Authors:  Donovan T Maust; H Myra Kim; Claire Chiang; Helen C Kales
Journal:  JAMA Intern Med       Date:  2018-05-01       Impact factor: 21.873

9.  Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.

Authors:  Paula T Trzepacz; Jeffrey Cummings; Thomas Konechnik; Tammy D Forrester; Curtis Chang; Ellen B Dennehy; Brian A Willis; Catherine Shuler; Linda B Tabas; Constantine Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-12-21       Impact factor: 3.878

10.  All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study.

Authors:  Rosa Liperoti; Graziano Onder; Francesco Landi; Kate L Lapane; Vincent Mor; Roberto Bernabei; Giovanni Gambassi
Journal:  J Clin Psychiatry       Date:  2009-10       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.